Investment
Features
FeesSafety
Academy
More
Pluang+

Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Neutral
Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox's board approved a quarterly cash dividend of $1.36 per share, payable on October 15, 2026, to shareholders recorded by September 30, 2026. This dividend reflects Lennox's ongoing commitment to returning value to its investors. Lennox is a leader in energy-efficient building solutions, serving both residential and commercial markets with heating, cooling, and air quality products. Investors can expect continued focus on innovation and customer lifecycle support from the company.

Lennox's quarterly dividend announcement provides context for readers interested in industrials. For readers following Industrials, here is Pluang's market snapshot as of Sep 18, 2026 21:32 WIB: Out of 76 priced US industrial stocks, 22 rose and 54 fell. Notable movers include RDW at USD 10.97 with a -5.02% change, TRMD at USD 38.27 with a +4.48% change, and SMR at USD 8.66 with a -4.42% change. Typical hold times range from 16 to 26 days with varying buy/sell order activity ratios.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Wells Fargo downgrades Netflix on weak viewer engagement and content concerns, cutting price target by 25%.

Wells Fargo downgrades Netflix on weak viewer engagement and content concerns, cutting price target by 25%.

Wells Fargo downgraded Netflix from "equal weight" to "underweight" citing weaker viewer engagement and concerns over content quality, which could pressure margins and valuation. The price target was cut to $57, implying a 25% downside from current l...

Analyst Insights
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App